Is BON or DFTX more undervalued in 2026?

CirclFi compares Bon Natural Life Limited (BON) and Definium Therapeutics, Inc. (DFTX) using 13 institutional-grade valuation models. BON has a Quality of Company score of 2.1/10 while DFTX scores 4.8/10.

Which is a better buy — BON or DFTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BON and DFTX valuations compare?

BON at $1.27 and DFTX at $24.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BON vs DFTX Valuation Comparison 2026 — Intrinsic Value Analysis

BON

Medicinal Chemicals & Botanical Products

Bon Natural Life Limited

Quality

2.1

out of 10

Value Trap

SAFE

Price

$1.27

Last close

Models

11/13

Active

DFTX

Medicinal Chemicals & Botanical Products

Definium Therapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$24.19

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	BON Fair Value	BON Upside	DFTX Fair Value	DFTX Upside
Bayesian DCF	Intrinsic	$0.26	-79.2%	$7.22	-70.2%
Earnings Power Value	Intrinsic	$0.28	-78.2%	$9.39	-58.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BON vs DFTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BON vs DFTX — Which Stock Is More Undervalued?

DFTX scores higher with a 4.8/10 quality rating vs BON's 2.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bon Natural Life Limited (BON) and Definium Therapeutics, Inc. (DFTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BON currently trades at $1.27 with a QOC of 2.1/10, while DFTX trades at $24.19 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).